Dr. Martin Gleave

Dr. Gleave

B.Sc. Physical Education, University of British Columbia
Doctor of Medicine, University of British Columbia
Fellow of the Royal College of Surgeons of Canada
Fellow, American College of Surgeons
Order of Canada

Board of Directors
Clinical and Research Scientists
Executive Team

Director, Vancouver Prostate Centre
Chief Executive Officer, PC-TRiADD
Distinguished Professor and Head, Department of Urologic Sciences, UBC
BC Leadership Chair in Prostate Cancer Research


Dr Gleave is a Distinguished Professor and Chair of the Department of Urologic Sciences at UBC, and a British Columbia Leadership Chair. He is a clinician-scientist and urologic surgeon, and Co-Founder and Executive Director of the VPC, a UBC and National Centre of Excellence, publishing > 625 papers with >60,000 citations, an H-Index of 125, and attracting >$120M in research funding. He was appointed to the Order of Canada for his leadership role in developing new treatments for prostate cancer and for his research on mechanisms mediating treatment resistance in cancer.

Dr. Gleave's clinical practice focuses on urologic oncology in a multi-disciplinary environment spanning localized and advanced cancers.  His research characterizes molecular mechanisms mediating treatment resistance in cancer, focusing on adaptive survival responses that drive acquired treatment resistance, and designing combination co-targeting strategies to create conditional lethality and improve cancer control. He patented several anti-cancer drugs and founded OncoGenex Pharmaceuticals to develop OGX-011 and OGX-427, inhibitors of cytoprotective chaperones clusterin and Hsp27 which progressed to Phase III and Phase II trials world-wide.  OncoGenex was awarded Canadian Biotech Company of the Year in 2010.  Dr. Gleave also recently co-founded TRiADD and Sustained Therapeutics.

Dr Gleave is the recipient of numerous awards, including the 2018 Dr. Chew Wei Memorial Prize in Cancer Research, the Huggins Medal from the SUO in 2018, the Richard Williams Award from the AUA in 2017, the Barringer Medal from the American Association of GU Surgeons; the Eugene Fuller Award from the American Urological Association in 2013; the Aubrey Tingle Prize from the Michael Smith Foundation for Health Research; and the NCIC William Rawls Award for contributions to cancer control in Canada; He was appointed a Distinguished University Scholar at UBC in 2003 and awarded a BC Leadership Chair in 2005. Dr Gleave was awarded the 2006 BC Biotech Award for Innovation and Achievement, and the 2007 BC Innovation Council Frontiers in Research Award.

Updated November 18, 2021

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.


Pars for Prostate fundraiser: September 22, 2022

The First Annual Pars for Prostate golf fundraiser in support of Prostate Cancer Foundation BC takes place September 22, 2022 at Westwood Plateau Golf Course. For information and to register please visit www.parsforprostate.ca

Dr. Black

Terry Fox Run fundraiser: September 18th, 2022

The 42nd Annual Terry Fox Run is taking place on Sunday September 18, 2022. If you are able, please consider joining and/or donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research


Work at the Vancouver Prostate Centre

Tuesday, September 20, 2022

Dr Mads Daugaard develops an AI cell analytics app which could supercharge biotechnology research

Wednesday, July 20, 2022

With just a tablespoon of blood, B.C. researchers aim to transform cancer treatment